Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

被引：0
|
作者：
Hai-Liang Zhang
Xi-Nan Sheng
Xue-Song Li
Hong-Kai Wang
Zhi-Hong Chi
Zhi-Song He
Ding-Wei Ye
Jun Guo
机构：
[1] Department of Urology,Department of Oncology
[2] Fudan University Shanghai Cancer Center,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma
[3] Shanghai Medical College,Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center
[4] Fudan University,undefined
[5] Peking University Cancer Hospital & Institute,undefined
[6] Peking University,undefined
来源：
BMC Cancer | / 17卷
关键词：
Metastatic renal cell carcinoma; Sorafenib; Sunitinib; Prognosis; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [22] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    Advances in Therapy, 2012, 29 : 202 - 217
  • [23] Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC.
    Tomita, Yoshihiko
    Naito, Sei
    Sassa, Naoto
    Takahashi, Atsushi
    Kondo, Tsunenori
    Koie, Takuya
    Obara, Wataru
    Kobayashi, Yasuyuki
    Teishima, Jun
    Takahashi, Masayuki
    Matsuyama, Hideyasu
    Ueda, Takeshi
    Yamaguchi, Kenya
    Kishida, Ken
    Shiroki, Ryoichi
    Saika, Takashi
    Nobuo, Shinohara
    Oya, Mototsugu
    Kanayama, Hiro-Omi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [24] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [25] Retrospective multicentric analysis of Indian patients with metastatic renal cell carcinoma on first-line sunitinib 2/1 schedule
    Patil, S.
    Thungappa, S.
    Kumar, K.
    Prasad, K.
    Tilak, T.
    Shashidhara, H. P.
    Somashekhar, S. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Lin, Jingyang
    Fang, Qingxia
    Zheng, Xiaochun
    PLOS ONE, 2023, 18 (02):
  • [27] Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC.
    Tomita, Yoshihiko
    Naito, Sei
    Sassa, Naoto
    Takahashi, Atsushi
    Kondo, Tsunenori
    Koie, Takuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [28] Re: Economic Evaluation of Everolimus Versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma After Failure of First-Line Sunitinib Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2012, 188 (01): : 68 - 69
  • [29] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [30] Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors
    Motzer, R. J.
    Michaelson, M. D.
    Hutson, T. E.
    Tomczak, P.
    Bukowski, R. M.
    Rixe, O.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 301 - 301
12345